Copyright
©The Author(s) 2017.
World J Gastroenterol. Dec 14, 2017; 23(46): 8182-8192
Published online Dec 14, 2017. doi: 10.3748/wjg.v23.i46.8182
Published online Dec 14, 2017. doi: 10.3748/wjg.v23.i46.8182
Table 4 Univariate and multivariate regression analyses of full and partial work disability in patients with Crohn’s disease n (%)
| Full disability | Partial disability | Unadj. OR (95%CI) | Adj. OR (95%CI) | |
| n | 342 (100) | 129 (100) | ||
| Sex (female) | 251 (73) | 100 (78) | 0.80 (0.50-1.29) | - |
| Age | ||||
| < 40 yr | 110 (32) | 54 (42) | 1.00 | 1.00 |
| 40-55 yr | 137 (40) | 61 (47) | 1.10 (0.71-1.72) | 1.05 (0.65-1.70) |
| > 55 yr | 95 (28) | 14 (11) | 3.33 (1.74-6.37) | 3.06 (1.54-6.07) |
| Age at diagnosis | ||||
| A1: diagnosis ≤ 16 yr | 28 (8) | 13 (10) | 1.00 | - |
| A2: diagnosis 17-40 yr | 256 (75) | 103 (80) | 1.15 (0.58-2.32) | |
| A3: diagnosis > 40 yr | 58 (17) | 13 (10) | 2.07 (0.85-5.05) | |
| Disease duration | ||||
| ≤ 15 yr | 151 (44) | 65 (50) | 1.00 | - |
| > 15 yr | 191 (56) | 64 (50) | 1.28 (0.86-1.93) | |
| Education | 332 (100) | 128 (100) | ||
| Low | 236 (71) | 73 (57) | 1.85 (1.21-2.83) | 1.62 (1.02-2.58) |
| Smoking | 323 (100) | 115 (100) | ||
| Yes | 125 (39) | 33 (29) | 1.57 (0.99-2.49) | 1.53 (0.93-2.50) |
| Disease location | ||||
| L1: ileal disease1 | 56 (19) | 21 (19) | 1.00 | - |
| L2: colon disease1 | 80 (28) | 38 (35) | 0.79 (0.42-1.49) | |
| L3: ileocolon disease1 | 155 (53) | 50 (46) | 1.16 (0.64-2.11) | |
| L4: upper GI disease2 | 38 (11) | 8 (6) | 1.89 (0.86-4.17) | - |
| P: peri-anal disease2 | 109 (32) | 45 (35) | 0.87 (0.57-1.34) | - |
| Disease behavior CD | ||||
| Fistulising disease2 | 64 (19) | 23 (18) | 1.06 (0.63-1.80) | - |
| Stricturing disease2 | 92 (27) | 33 (26) | 1.07 (0.67-1.70) | - |
| Penetrating disease2 | 47 (14) | 19 (15) | 0.92 (0.52-1.64) | - |
| Pouch2 | 6 (1.8) | 4 (3) | 0.56 (0.15-2.01) | - |
| Stoma2 | 69 (20) | 20 (16) | 1.38 (0.80-2.38) | - |
| Surgery2 | 192 (56) | 64 (50) | 1.30 (0.87-1.95) | - |
| Medication | 335 (100) | 125 (100) | ||
| Anti-TNFα | 193 (58) | 68 (54) | 1.14 (0.75-1.72) | - |
| Immunomodulators | 249 (74) | 87 (70) | 1.26 (0.80-1.99) | - |
| Extra-intestinal manifestations2 | 152 (44) | 50 (39) | 1.26 (0.84-1.91) | - |
| PSC2 | 2 (0.6) | 4 (3) | 0.18 (0.03-1.02) | 0.19 (0.03-1.10) |
| Complications2 | 106 (31) | 34 (26) | 1.25 (0.80-1.98) | - |
- Citation: Spekhorst LM, Oldenburg B, van Bodegraven AA, de Jong DJ, Imhann F, van der Meulen-de Jong AE, Pierik MJ, van der Woude JC, Dijkstra G, D’Haens G, Löwenberg M, Weersma RK, Festen EAM, Parelsnoer Institute and the Dutch Initiative on Crohn and Colitis. Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(46): 8182-8192
- URL: https://www.wjgnet.com/1007-9327/full/v23/i46/8182.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i46.8182